GlassScriptPhysician profile
Samer Mossallam
NPI 1578545638
$7,840.90
in general payments reported to CMS, 2019-2025
31 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,842 · 2020: $155 · 2021: $785 · 2022: $859 · 2023: $604 · 2024: $219 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $4,515.25 | 2019 | |
| Abbvie INC. | $549.90 | 2019-2025 | |
| Myovant Sciences INC. | $494.54 | 2021-2022 | |
| Hologic Sales and Service, LLC | $464.60 | 2019-2025 | Coolseal Generator, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Mayne Pharma Commercial LLC | $263.75 | 2023-2025 | |
| Astellas Pharma US INC | $260.24 | 2022-2025 | Veozah |
| Novo Nordisk INC | $228.59 | 2019-2025 | Wegovy |
| Aspira Women'S Health INC | $181.93 | 2019-2022 | |
| Sage Therapeutics, LLC | $113.84 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $103.63 | 2019-2022 | |
| Pfizer INC. | $78.98 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $72.05 | 2023-2025 | Myfembree |
| Channel Medsystems, INC. | $67.38 | 2022-2023 | |
| Coopersurgical, INC. | $60.44 | 2021-2025 | Paragard T 380a |
| Ascend Therapeutics US, LLC | $49.51 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $43.39 | 2019 | |
| Agile Therapeutics, INC. | $40.06 | 2022 | |
| Daiichi Sankyo INC. | $31.73 | 2019-2021 | |
| Amgen INC. | $27.82 | 2021-2023 | Evenity, Prolia |
| Shield Therapeutics INC | $21.97 | 2023 | Accrufer |
| Boston Scientific Corporation | $21.67 | 2023 | Wavewriter Alpha Prime 16 |
| Evofem Biosciences, INC. | $19.98 | 2022 | |
| Axonics, INC. | $17.91 | 2023 | Bulkamid |
| Allergan, INC. | $17.25 | 2019 | |
| Becton, Dickinson and Company | $15.75 | 2023 | Bd Surepath Collection Vial |
| Baxter Healthcare | $14.50 | 2022 | |
| Ethicon US, LLC | $14.01 | 2019 | |
| Meditrina | $13.47 | 2023 | |
| Exeltis, USA INC. | $13.19 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.15 | 2020 | |
| Avion Pharmaceuticals | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Mossallam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.